Injection needle and device

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Tripep Ab patent solves the following problem:

The delivery of therapeutic materials, such as genetic material, to tissue that has a wide range of useful applications including vaccination, replacement of a defective gene, DNA immunization, introduction of an immunogen, anti-sense therapy, and miRNA, RNAi, aptamer, or siRNA therapy. For example, nucleic acid, such as DNA, for example, can be injected into the tissue, where the nucleic acid derived from the surrounding cells inefficiently. DNA introduced in this way a protein encoding DNA. The successful delivery of nucleic acid into the tissue and the uptake of nucleic acid into cells is difficult, especially when a significant amount of protein expression was determined (for example, as desired for DNA-based vaccination ). Conventional injection of genetic material into tissues in general result in poor uptake in cells and low levels of protein expression, if any at all.

Our analysis of this patent is as follows:

Tripep Ab’s patent US 9457183 B2 deals with Injection needle and device.
Some needle assemblies and intracellular delivery devices used for delivery of prophylactic and / or therapeutic material (ie, given agent) into a tissue of a subject expressed. At best, the needle assemblies and / or intracellular delivery device comprises a needle and / or needle electrodes, disposed in a forest (for example, a Y-type war with three outer needle with a center the needle), where each needle in the forest is a closed end and a plurality of apertures along each needle barrel, and the apertures of the needle gun out war needle position to deliver delivered agents into the apertures in the center pin and / or a neighboring needle, but not without the active zone defined area within the cloud forest and the apertures in the needle barrel in center needle position to deliver vicarious agents toward the outer needle.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Vision training system

Use PowerPatent’s Online Patent Filing Service to get quick patent protection for your great idea.

The Dacks Rodriguez patent solves the following problem:

It is important for baseball hitters in recognition not only of different kinds of pitches pitched in a pitcher but also to discern the pitched ball in the strike zone or zone to be successful.

Our analysis of this patent is as follows:

Dacks Rodriguez’s patent US 9457253 B1 deals with Vision training system.
Devices, systems, and methods for training baseball and softball beat, in their eyes the ball up (fast ball, curve ball, slider and changeup) and place (strike or non-strike zone) pitched the ball to adding sufficient accuracy. A motion sensor will be triggered in the first legs in a jar. The motion sensor can face up to them to throw a ball up from the jar. When the motion sensor that causes a signal to be sent to a black out lens that blocks the vision of a hitter trained in identifying species and areas in pitched ball. The training includes the lens transparent to opaque at chosen distance between the hitter and pitcher.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Deveining system and device

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The Laitram, L.L.C. patent solves the following problem:

To prepare the shrimp, crawfish or other animals that have a root in the alimentary canal, it is often desirable to remove the vein. Current options for deveining shrimp include manual removal, which is inefficient and time-consuming, and automated device known in the art. With manual operation, a worker must perform a number of operations to partially or completely remove the shell from the meat of shrimp, and cut the meat with shrimp way desirable to the end user. Manual vein removal is relatively time consuming and thus lead to higher costs. Moreover, the recent contacts between the workers and the shrimp can lead to contamination of shrimps. Furthermore, the process results to be less than uniform depending on individual workers to perform the operation, and the diligence of the workers process shrimp.

Our analysis of this patent is as follows:

Laitram, L.L.C.’s patent US 9456617 B2 deals with Deveining system and device.
A deveining device efficiently removes the vein from the shrimp while preserving the meat of shrimp in both form and number. Deveining device consists of a channel that has a blade extending along a section of the canal to cut back on shrimp as it rolls through the channel to expose a vein. A low root remover severs the exposed vein from the shrimp body. Nozzles spray fluid channel to maintain shrimp by the way.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Shuffled playing cards and manufacturing method thereof

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with PowerPatent’s Utility, Provisional or Design Patent Filing Software

The Angel Playing Cards Co., Ltd. patent solves the following problem:

In poker, baccarat, bridge, blackjack, and other card games, a dealer set in one or more decks of playing cards in a card shooter or the like, and reference cards Game players by shooting cards from the card shooter or the like. In doing so, to ensure justice in the game, the cards should be made at random. Therefore, a multitude of games there Shuffle the cards randomly enough before playing cards set the card shooter.

Our analysis of this patent is as follows:

Angel Playing Cards Co., Ltd.’s patent US 9457262 B2 deals with Shuffled playing cards and manufacturing method thereof.
The present invention provides shuffled cards that eliminate the need for a multitude of games to shuffle cards before games by taking a lot of time as well as to eliminate the possibility of cheating. A shuffled cards (1) obtained by shuffling a predetermined number of decks of playing cards (12) use a shuffling machine that packaged as an individual pack. The shuffled cards (1) is individually packaged and sealed with an adhesive (13). A bar code (13 a) represents a unique shuffled card ID printed on the adhesive label (13). The shuffled card ID registered in a database in association with information that allows the identification of a shuffling machine used to shuffle the playing card set.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Container for the generation of therapeutic microfoam

Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Btg International Limited patent solves the following problem:

Sclerosis of varicose veins is based on vein injection of liquid sclerosant substances which, by inter alia causing a localized inflammatory reaction, favor the elimination of these abnormal veins. Until recently, sclerotherapy was a technique selected in cases of small and medium caliber varicose veins, those with diameters equal to or greater than 7 mm being treated by surgery. Sclerotherapy and operation nagkakomplimento one another, but to treat with sclerotherapy continues to apply to large varicose veins. In these large varicose veins, if a sclerosing liquid is injected, the amount of liquid sclerosant necessary to fill the entire length of the varicose vein exceeded safe limits dose to normal sclerosant concentration, and may be effective concentration needed to limit the dose to safe levels. Furthermore, its concentration in the vein, the uniform distribution of blood, and the period for which it is in contact with the internal walls of the vessel treated were not known.

Our analysis of this patent is as follows:

Btg International Limited’s patent US 9457160 B2 deals with Container for the generation of therapeutic microfoam.
Device containing sclerosant liquid for use in the treatment of blood vessels with an aerosol valve housing containing a gas entry port. The aerosol valve housing sitting in a canister containing an expandable inner vessel which sclerosant fluid available. The expandable container affixed to the outer opening of the canister or aerosol valve housing on the gas valve port-entry to gas taken from within the expandable container can mix with sclerosant liquid to make a micro bubbles, so that the introduction of pressurized gas through the aerosol valve causing expandable container to inflate to accommodate the pressurized gas.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Bis-acylated hydroxylamine derivatives

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Cardioxyl Pharmaceuticals, Inc., , The Johns Hopkins University patent solves the following problem:

Our analysis of this patent is as follows:

Cardioxyl Pharmaceuticals, Inc., , The Johns Hopkins University’s patent US 9458127 B2 deals with Bis-acylated hydroxylamine derivatives.
invention provides several bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invention provides methods of using such compounds or medicine composition for treating, preventing, or delaying the onset and / or develop a disease or condition. In some embodiments, the disease or condition is selected from cardiovascular disease, ischemia, reperfusion injury, cancerous disease, pulmonary hypertension and the condition responsive to nitroxyl therapy.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for inducing cell death in acute lymphoblastic leukemic system cells

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Cantargia Ab patent solves the following problem:

Chronic myeloid leukemia (CML) is the first human neoplasm associated with a recurrent genetic aberration; Philadelphia (Ph) chromosome, formed by a corresponding transition between chromosome 9 and 22, giving rise to a constitutively activated tyrosine kinase BCR / ABL11. In CML, Ph chromosome is believed to originate from a hematopoietic stem cell (HSC) as it clonally found in malignant myeloid cells and non-malignant lymphoid cells2. The Ph chromosome is found in a part of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). CML composed of heterogeneous cell in various stages maturation maintained by a small number of cells, called CML stem cells, sharing the capacity of self-renewal of normal HSC3 . This shows that CML stem cells at least partially resistant to current treatments tyrosine kinase inhibitors4,5, despite clinical success demonstrated a suppressive rather than curative effects of this disease. Therefore, recognition of a way to efficiently target CML stem cells very attractive to achieve a permanent cure for the disease. Such a strategy to identify a target in CML stem cells provide a novel means to eliminate CML stem cells. Encouraging reports its direction described in the related disorder acute myeloid leukemia (AML), where the antibody target CD123, CXCR4, CD44 or CD47 in AML stem cells to express anti-leukemic effects in animal AML models6-9. Furthermore, AML stem cell associated antigens CD96 and CLL-1 identified10,11, providing additional targeted candidates of this disease. Surprisingly, even in one of the most studied neoplasms of all time, called a cancer stem cell disorder, no cell surface biomarker so far recognized the CML that allows a future separation of CML stem cells in normal HSCs, when the rare CD34 + CD38 cell population12,13. Recognizing that a biomarker tool to characterize the CML stem cells, but can also be used for new treatment developments and for tracking therapeutic effects of ancient CML cells during treatment.

Our analysis of this patent is as follows:

Cantargia Ab’s patent US 9458237 B2 deals with Method for inducing cell death in acute lymphoblastic leukemic system cells.
The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and / or inhibiting the growth and / or proliferation pathological cells in the stem and / or progenitor cells associated with a neoplastic hematologic disorder, in which the cells expressing IL1RAP. A related aspect the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in identifying pathological stem cells and / or fathers cells associated with a neoplastic hematologic disorder, in which the cells expressing IL1RAP. Moreover given the medicine composition containing the agents to devise methods of using the same.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Motor vehicle inspection device and method for identifying motor vehicles

File for Quick & Easy Patent Protection with PowerPatent.

The Robert Bosch Gmbh patent solves the following problem:

Unexamined patent application DE 199 42 844 A1 describes a system for the identification of the vehicle during the inspection of a test lane.

Our analysis of this patent is as follows:

Robert Bosch Gmbh’s patent US 9460132 B2 deals with Motor vehicle inspection device and method for identifying motor vehicles.
A method for identifying a motor vehicle for a plurality of devices that motor vehicle inspection, including the knowledge of a race car character; to determine basic data on their vehicles; hide quirks and the basic identification data of an identification data for this car to a storage medium; recognition to the knowledge of the data set associated with the vehicle storage medium based on a different character with a first plurality of motor vehicles dodge inspection; reading the data known to them to put the car out of storage medium; to determine the first data to identify vehicles, which are specific to the first plurality of motor vehicles dodge inspection; increase the read-out of the identification data set in the first data to them; storing more data to identify the storage medium; recognition to the knowledge of the data set associated with the vehicle storage medium based on a different character with a second plurality of motor vehicles dodge inspection; reading the data known to them to put the car out of storage medium; to determine the second data identifying the vehicles, which are specific for the second plurality of motor vehicles dodge inspection; increase the read-out of data identification placed second data to them; and gather further data to identify the storage medium.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Powered ambulance cot with an automated cot control system

Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Ferno-Washington, Inc. patent solves the following problem:

There is a kind of emergency patients delivered in use today. The emergency patient transporting can be designed to carry and load Bariatric patients into an ambulance. For example, the PROFlexX bed, by Ferno-Washington, Inc. Wilmington, Ohio USA, is one of those vehicles that are patient as a hand operated cots that provide strength and support for loads of 700 pounds (317,5 kg) . PROFlexX bed includes a patient support portion attached to a wheel undercarriage. The wheels under carriage includes an X-frame geometry to be transitioned between nine selectable positions. A recognized advantage of such a bed design is that the X-frame provides minimal flex and a low center of gravity for all of the selectable positions. Another recognized the advantage of such a bed design is the selectable position to provide better leverage manually lifting and loading Bariatric patients.

Our analysis of this patent is as follows:

Ferno-Washington, Inc.’s patent US 9456938 B2 deals with Powered ambulance cot with an automated cot control system.
A powered ambulance cot and upbringing and humble bed as well as loading and unloading the bed made. bed includes a support frame and legs, each leg with a wheel. An actuator with an actuation system to connect the frame and legs, and configured to effect changes in the length of the frame relative to the wheel of each of the legs. A control system controls activation of the actuation system, and detects the actuator at a first location relative to the frame, where the first location remote from a second place and a hard end actuator remote from each wheel closer to the frame, and a presence of a signal requesting a change in the length of said support frame so causes the foot to move relative to the frame support.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Combination therapy using c-Met inhibitor and beta-catenin inhibitor

File for Quick & Easy Patent Protection with PowerPatent.

The Samsung Electronics Co., Ltd. patent solves the following problem:

If a method of preventing and / or treating a cancer, the method including the co-administration of a c-Met inhibitor and a beta-catenin inhibitor to a subject in need it.

Our analysis of this patent is as follows:

Samsung Electronics Co., Ltd.’s patent US 9457081 B2 deals with Combination therapy using c-Met inhibitor and beta-catenin inhibitor.
A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit consisting of a pharmaceutical composition containing a c-Met inhibitor and a pharmaceutical composition containing a beta-catenin inhibitor packaged together.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.